Pédiatrique divers

DISEASE CHARACTERISTICS:

• Diagnosis of primary cancer at age 21 or younger
• No prior history of allogeneic (non-autologous) hematopoietic cell transplant

• In active follow-up by a Children's Oncology Group (COG) institution

  • Date of last visit or contact by a COG institution within the past 24 months

• Case group

  • Development of one of the following key adverse events after initiation of prior cancer therapy:

    • Cardiac dysfunction, meeting 1 of the following criteria:

      • Symptomatic cardiac dysfunction, including current or previous diagnosis of congestive heart failure based on any of the following clinical criteria:

        • Pulmonary and/or peripheral edema
        • Dyspnea
        • Orthopnea
        • Fatigue
        • Hepatomegaly

      • Asymptomatic cardiac dysfunction

        • Ejection fraction < 40% on echocardiogram OR MUGA and/or fractional shortening < 28% on echocardiogram without clinical symptoms

    • Myocardial infarction, meeting 1 of the following criteria (closed to accrual as of 6/5/06):

      • Definite ECG changes
      • Typical, atypical, or inadequately described symptoms AND probable ECG, AND abnormal enzymes, including creatine kinase MB
      • Typical symptoms AND abnormal enzymes, including creatine kinase MB, AND ischemic ECG, non-codable ECG, or ECG not available

    • Ischemic stroke, meeting the following criteria:

      • Fixed neurological deficit lasting more than 24 hours
      • Confirmed by CT scan or MRI within 7 days of onset of symptoms
      • No subarachnoid or intracerebral hemorrhage, transient ischemic attacks, or amaurosis fugax

    • Avascular necrosis, meeting the following criteria:

      • Clinical symptoms of joint pain, joint stiffness, or decreased range of motion
      • Confirmed by plain radiographs, CT scan, MRI, or bone scan

    • Subsequent malignant neoplasm, meeting the following criteria:

      • Histologically distinct neoplasm developing in patients treated for a primary cancer
      • Confirmed by an institutional pathology report

• Control group

  • No clinical evidence of any of the following:

    • Cardiac dysfunction
    • Myocardial infarction (closed to accrual as of 6/5/06)
    • Ischemic stroke
    • Avascular necrosis
    • Subsequent malignant neoplasm